

Redefine the reach of reliable testing

cobas® Plasma Separation Card



SPOT IT. MOVE IT. PROVE IT.

Helping HIV communities that face the toughest challenges

Where access to power supplies is unreliable...

Where transport can be a long and arduous task...

Where HIV/AIDS hits communities hardest...

Innovative sample collection options can make reliable testing available to those who need it most.

As the world's leading provider of HIV viral load testing, Roche is committed to realising universal access to reliable HIV testing; the HIV Global Access Program aims to contribute to the UNAIDS 90-90-90 goal

Introducing the cobas® Plasma Separation Card

Take Aim at HIV – Let's help tackle the HIV/AIDS epidemic by making sample collection simple and achievable in remote and challenging areas



Meet the needs of remote collection and maintain confidence in results

- Create plasma samples without the need for phlebotomists, electricity or centrifuges
- Simply label the card, apply whole blood, and dry on the rack
- Deliver it to the lab in the bag supplied
- Peel the membrane, elute the plasma, and test to get reliable results
- Compatible for use on COBAS® AmpliPrep/ COBAS® TaqMan® and **cobas**® 6800/8800 Systems



SPOT IT. MOVE IT. PROVE IT.

Benefits for remote, diverse, underfunded areas

Decentralised collection meets high-throughput centralised testing

Preferred sample type

- For reliable HIV viral load monitoring, plasma is the gold-standard sample type¹
- Plasma samples are free from the excess RNA/DNA found in whole blood
 - Helping you distinguish true signals from background noise

Simple transportation

- No refrigeration or complex processing required
- Stable at high temperatures and humidity
- Suitable for the demands of diverse infrastructure



Reliable, sensitive results

- Dried blood spot viral load monitoring is less accurate than plasma viral load testing, resulting in misclassification of viral load suppression²
- **cobas**[®] Plasma Separation Card enables accurate detection of HIV treatment failure, with a limit of plasma detection <1000 cps/ml (the threshold recommended by WHO)

Take testing to a new level with **cobas**[®] Plasma Separation Card



Global Access Program
take aim
at HIV

References:

1. Holodniy M, Mole L, Yen-Lieberman B et al. J Clin Microbiol 1995; 33(6):1562–1566.
2. Pannus P, Claus M, Perez Gonzalez MM et al. Medicine 2016; 95:48(e5475)..

Find out more about the HIV Global Access Program at
<https://molecular.roche.com/about/global-access-program/>

COBAS, TAQMAN, AMPLIREP are trademarks of Roche.

© 2017 Roche

Published by:
Roche Molecular Systems
4300 Hacienda Drive
Pleasanton, CA 94588
USA